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Background: To investigate the role of Kodama PenA subtype in influencing survival in patients with
early gastric cancer (EGC).
Methods: All patients surgically treated for EGC at 7 Italian centers (Forlì, Varese, Siena, Verona, Milan,
Rome and Perugia) belonging to the Italian Research Group for Gastric Cancer (GIRCG) from January 1982
and December 2009 were included.
Results: PenA patients were 230 (21.5%) while other types were 839 (78.5%). Nodal metastases were
more common in PenA (30.7%) than non-PenA (10.4%) EGCs. Among preoperative variables, only age (OR
1.02; 95% CI 1.00e1.03, p ¼ 0.009) and macrotype III (OR 1.95; 95% CI 1.39e2.75, p ¼ 0.0001) were
significantly associated with Pen A type. Survival analysis performed on N0 patients demonstrated that
only size >2 cm (HR 1.85; 95% CI 1.12e3.05, p ¼ 0.017) and age (HR 1.06; 95% CI 1.03e1.08, p < 0.0001)
were independent poor prognostic factor. Among Nþ patients age (HR 1.04; 95% CI 1.00e1.07, p ¼ 0.048),
number of positive lymph nodes (HR 1.13; 95% CI 1.05e1.20, p ¼ 0.0002) and PenA (HR 4.23; 95% CI 1.70
e10.55, p ¼ 0.002) were significantly correlated with poor prognosis at multivariate analysis.
Conclusions: Kodama PenA subtype was the most powerful independent prognostic factor in patients
with nodal metastases. Its status should always be investigated in EGCs patients.
© 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
Early gastric cancer (EGC) is associated with a 5-year survival of
more than 90% [1e3]. However, a subgroup of EGC patients shows agery, Department of Surgery,
magna, Forlì, Italy.
ini).
on for Cancer Surgery, and the Eursignificantly worse prognosis. This has been partly explained by the
presence of lymph node metastases which has been shown as a
powerful factor influencing survival in EGCs [4e6]. Previous GIRCG
multicenter analyses on EGC patients confirmed the importance of
N status as a prognostic factor and also showed that Kodama's PenA
type was an independent predictor of poor prognosis [4,5].
Nevertheless, data about clinico-pathological features of the
Kodama's Pen A type are scarce in literature. With this paper we
aim to investigate the characteristics of Pen A type, focusing our
analysis on its impact on survival.opean Society of Surgical Oncology. All rights reserved.
Fig. 1. Scheme representing Kodama's types.
Table 1
Patients' and tumor characteristics.
Kodama p
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Study populations and definitions
All patients surgically treated for EGC at 7 Italian centers (Forlì,
Varese, Siena, Verona, Milan, Rome and Perugia) belonging to the
Italian Research Group for Gastric Cancer (GIRCG) from January
1982 and December 2009 were included. Local Ethical Committee
approved this study. Informed consent was not required due to the
retrospective nature of the study.
As per GIRCG guidelines, the included centers routinely use
commonly-defined diagnostic and surgical criteria [7].
All slides were re-revised according to the current guidelines [7]
by the dedicated pathologists of each centres.
The EGCs were classified according to macroscopic and micro-
scopic criteria proposed by the Japanese Society of Gastroenter-
ology and Endoscopy (JSGE) and Lauren, respectively [8,9]. ECGwas
also stratified as per Kodama classification (Fig. 1) [10].
Cancer specific survival, which was the only time-related vari-
able used in the analysis, was defined as the interval from the date




No. (%) No. (%)
Age n (%) - n ¼ 1046 - 0.01
60 years 50 (22) 252 (31.2)
>60 years 177 (78) 567 (69.2)
Sex n (%) 0.179
Male 124 (53.9) 496 (59.1)
Female 106 (46.1) 343 (40.9)
Lauren's histotype n (%) - n ¼ 1068 - 0.133
Intestinal 173 (75.6) 585 (69.7)
Diffuse 35 (15.3) 178 (21.2)
Mixed 21 (9.1) 76 (9.1)
Size n (%) - n ¼ 1060 - 0.016
2 cm 114 (50.2) 495 (59.4)
>2 cm 113 (49.8) 338 (40.6)
N stage n (%) - n ¼ 1057 - <0.001
N0 157 (69.2) 744 (89.6)
N1 52 (22.9) 63 (7.6)
N2 17 (7.4) 19 (2.3)
N3 1 (0.4) 4 (0.5)
Macrotypes (JSGE) - n ¼ 1051 - <0.001
I (polypoid) 36 (16.1) 101 (12.2)
IIa (elevated) 27 (12.0) 88 (10.6)
IIb (flat) 7 (3.1) 100 (12.1)
IIc (depressed) 86 (38.4) 390 (47.2)
III (excavated) 68 (30.4) 148 (17.9)Statistical analysis
The chi-square test was used to compare categorical data.
Continuous data, which were presented as median and inter-
quartile range (IQR) were compared using Mann Whitney U test.
Sex, age, tumor size (2 vs >2), Lauren histotypes and macrotypes
according to JSGE (type III vs non type III) were analyzed with lo-
gistic regression to assess whether they could predict the diagnosis
of PenA. Odds ratio (OR) and 95% confidence interval (95% CI) were
calculated when required.
Cox proportional-hazards regression was performed to find
those factors influencing cancer-specific survival in the subgroup
of N0 and Nþ patients. Included variables were Sex (female vs.
male), age, tumor size (2 vs >2), number of positive lymphn-
odes, Lauren's histotypes, macrotypes according to JSGE (type III
vs non type III), and PenA status (PenA vs non-PenA). Hazard
ratios (HR) and 95% confidence interval (95% CI) were calculated
when required.
A p value < 0.05 was considered statistically significant. Statis-
tical analysis was performed with MedCalc Statistical Software
version 15.8 (MedCalc Software bvba, Ostend, Belgium; https://
www.medcalc.org; 2015).Results
Data about Kodama subtypes were available for 1069 out of 1074
EGC patients. Six hundred and twenty (58%) were men and 448
(41.9%) women with a median of 67 years of age (range 22e93
years). Kodama PenA were 21.5% (n ¼ 230).
Patients' characteristics grouped according to their PenA status
are reported in Table 1.
The median number of lymph nodes harvested was 15 (IQR
10e25) and there was no significant differences between PenA
(median 16; IQR 11e26) and non-PenA (median 15; IQR 10e24)
(p ¼ 0.366). Multivariate analysis showed that age (OR 1.02; 95% CI
1.00e1.03, p ¼ 0.009) and macrotype (JSGE) III (OR 1.95; 95% CI
1.39e2.75, p ¼ 0.0001) were significantly associated with Pen A
type (AUC 0.59; 95% CI 0.56e0.62). Median follow-up was 193
months (range 1e324).Survival analysis
Multivariate analysis performed on N0 patients (n ¼ 901)
demonstrated that only size >2 cm (HR 1.85; 95% CI 1.12e3.05,
p ¼ 0.017) and age (HR 1.06; 95% CI 1.03e1.08, p < 0.0001) were
significantly correlated with a poor prognosis (Table 2). Ten-year
survival was 94.3% for tumors 2 cm while it was 89.2% when
size was above 2 cm (p ¼ 0.0032) (Fig. 2). Among N positive pa-
tients (n ¼ 156) age (HR 1.04; 95% CI 1.00e1.07,p ¼ 0.048), number
of positive lymph nodes (HR 1.13; 95% CI 1.05e1.20, p¼ 0.0002) and
PenA (HR 4.23; 95% CI 1.70e10.55, p ¼ 0.002) were the only in-
dependent prognostic factors (Table 2). N-positive PenA patients
showed a 10-year survival of 63.8% while it was 89.3% for other N
positive Kodama types (p ¼ 0.0004) (Fig. 3).
In the whole cohort of 1069 patients PenA had a significantly
lower 10-year survival (78.2%) when compared with other sub-
mucosal non-PenA (91.5%) and mucosal (94.2%) EGC (p < 0.0001)
Table 2
Cox regression analyses for N and Nþ EGC patients.
Variables N Nþ
Univariate Multivariate Univariate Multivariate
HR (95% CI) P HR (95%CI) P HR (95% CI) P HR (95% CI) P
Female (yes vs no) 0.77 (0.47e1.28) 0.331 1.17 (0.57e2.39) 0.666
Agea 1.06 (1.03e1.09) <0.0001b 1.06 (1.03e1.08) <0.0001 1.03 (1.00e1.06) 0.049b 1.04 (1.00e1.07) 0.048
Tumor size >2 cm (yes vs no) 2.08 (1.27e3.41) 0.004b 1.85 (1.12e3.05) 0.017 0.75 (0.37e1.53) 0.442
Number of positive lymph nodesa 1.1 (1.04e1.17) 0.0005b 1.13 (1.05e1.20) 0.0002
Lauren's histotypes
Diffuse (yes vs no) 0.61 (2.95e1.29) 0.202 0.84 (0.4e1.77) 0.654
Intestinal (yes vs no) 1.35 (0.75e2.44) 0.314 0.98 (0.48e2.02) 0.966
Mixed (yes vs no) 1.08 (0.46e2.49) 0.854 1.35 (0.55e3.29) 0.507
JSGE macrotypes type III (yes vs no) 1.02 (0.55e1.87) 0.954 1.17 (0.53e2.54) 0.696
Kodama PenA type (yes vs no) 1.87 (1.06e3.28) 0.031b 3.9 (1.74e8.73) 0.001b 4.23 (1.70e10.55) 0.0004
a Analyzed as continuous variable
b Included in the multivariate analysis.
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submucosal non-PenA and mucosal EGC patients was 84.9 and
96.3%, respectively (Fig. 4b).
Discussion
PenA Kodama type, which represents more than one fifth of all
EGCs, is associated with worse prognosis than the other types. This
has already been shown by previous studies from our group [4e6].
Differently from these papers, we reported data about a large
cohort of 1069 EGC patients, focusing our analysis on the clinico-
pathological characteristics of PenA vs other EGC types and on
the impact of PenA type in the prognosis of patients according to
nodal status. Our analysis confirmed that PenA is a negative prog-
nostic factor especially in patients who are N positive. Among them,
non-PenA patients reached a plateaux in terms of survival after 5
years while this is delayed by fivemore years for PenA patients. This
result may suggest that a prolonged follow-up of at least 10 years
should be always considered in ECG PenA type patients.Fig. 2. Kaplan-Meier curves showing survival probabIt has already been demonstrated that the submucosal invasion
is a negative prognostic factor in EGC [5]. In order to verify whether
the pattern of invasion could significantly influence survival among
EGCs invading submucosa, we compared PenA with other submu-
cosal types of EGC. This analysis demonstrated that PenA was
significantly associated with the worst prognosis among
submucosal-invading EGCs, showing that the pattern of invasion
was the key factor affecting prognosis.
As it also appeared from our data, PenA displayed a significantly
higher incidence of nodal metastases than the other EGCs subtypes
[4,5]. PenA was found as a significant risk factor for lymph node
spread in a previous analysis on 584 EGC patients by GIRCG [4].
According to these findings PenA patients may benefit from a
standard gastrectomy with D2 lymphadenectomy. This would be in
contrast with current guidelines, in which a D1þ lymphadenec-
tomy could be considered a radical procedure for EGCs [7,11].
Consequently, it may not be appropriate to attempt either more
conservative or endoscopic-assistedminimally invasive approaches
in PenA EGCs [12e14].ility according to tumor size (>2 cm vs. 2 cm).
Fig. 3. Kaplan-Meier curves showing survival probability according to Kodama's type (PenA vs other types).
Fig. 4. Kaplan-Meier showing survival probability of PenA vs Other submucosal vs Mucosal types in the whole cohort (A) and in Nþ patients (B).
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operatively and, therefore, to offer EGC patients the most adequate
treatment. Our analysis found age and JSGE macrotype III as the
only predictor variables positively associated with PenA type. Un-
fortunately, these two variables are too uncertain and their pre-
dictor model showed a very low accuracy with an AUC of 0.59 (95%
CI 0.56e0.62).
Currently, the research institute of one of the GIRCG centres
(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
(IRST)) has been investigating potential biochemical and molec-
ular markers which may help in identifying PenA at an early
stage of the diagnostic process. This study has some limitations
mainly due to the retrospective nature of the analysis. First, the
study interval is very wide and it may have included different
modalities of care for the patients. Second, we could not provide
information about patients who underwent adjuvant chemo-
therapy and, thus, we could not verify whether, among N positivepatients, there would have been differences between the two
groups in terms of adjuvant treatments. Third, pathological fac-
tors, like lymphovascular invasion, which might have had an
impact on survival, could not be retrieved and were not included
in the analysis.
In conclusion, we showed that, in patients with nodal metas-
tases, Kodama PenA subtype was the most powerful independent
prognostic factor. Its status should always be investigated in EGCs
patients, who should benefit from a D2 lymphadenectomy and a
10-years long follow up.
Further studies are needed with the aim of identifying PenA
preoperatively in order to address patients to the most appropriate
treatment option.
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